At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 207 enrolled
Drug / intervention
Brivaracetamdrug
Likely dose
Brivaracetam 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multicenter, Follow-up Study to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization
In Brief
A Phase 3 clinical trial evaluating Brivaracetam for Partial Seizures With or Without Secondary Generalization and Epilepsy. Completed, enrolled 207 participants across 59 sites in 2 countries.
Detailed Summary
The purpose of the study is to evaluate the long-term safety and tolerability of Brivaracetam (BRV) in focal epilepsy subjects with partial seizures and to evaluate the maintenance of efficacy of BRV over time.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina, Japan
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
Enrollment StartAug 2017
First PostedAug 2017
Primary CompletionDec 2024
TodayJul 2026
First PostedAug 15, 2017
Enrollment StartAug 5, 2017
Primary CompletionDec 24, 2024
TodayJul 2, 2026
Enrollment to primary: 7.4 yearsPosted 8.9 years ago
Interventions
Brivaracetamdrug
* Pharmaceutical form: Film-coated tablet * Concentration: 25 mg and 50 mg * Route of administration: Oral use